mTOR and cancer: reason for dancing at the crossroads?
Recent successes using Gleevec for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors have provided proof that strategies to target signal transduction pathways mutated in human cancers can work. However, the application of this strategy to other cancers has been slow. Central to alleviating this impedance is the molecular characterization of the tumors. There is an urgent need to translate basic scientific findings into relevant, clinically applicable molecular diagnostic assays.
Thomas
George V
GV
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California Los Angeles, A7-149 Center for Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095-1732, USA. gvthomas@mednet.ucla.edu
D000818:Animals; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D011494:Protein Kinases / Q000502:physiology*; D015398:Signal Transduction; D020123:Sirolimus / Q000031:analogs & derivatives / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases
D014408:Biomarkers, Tumor; C401859:temsirolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus